PARP inhibitors represent promising agents for BRCA1/2 mutant patients within this highest risk population; inhibitors of the WNT/β-catenin pathway represent further agents worthy of investigation in this subtype given the high frequency of mutation in SOX8. IHC for PR and p53—both of which are already performed within the routine diagnostic pipeline for ovarian tumours—represents a readily implementable approach for identifying high- and low-risk EnOC patient groups. The gene discussed is TP53; the disease is ovarian neoplasm.